Thursday, 30 June 2011

Neptune Subsidiary - Acasti - Off To Clinical Races

Neptune Technologies & Bioressources
Basic Shares: 48.2 million
Fully diluted: 53.9 million


Neptune's 60%-owned subsidiary, Acasti Pharma, is just 12 to 18 months away from seeing how much gold may be at the end of the rainbow after Health Canada gave its blessing to a phase 11 clinical trial of Acasti's drug candidate, CaPre.

That's how long it is estimated to take to conduct the randomized, double blind, placebo-controlled human trials to determine how effectively CaPre lowers bad cholesterol, increases good cholesterol and lowers blood fats called triglycerides. The stakes are huge, literally in the billions of dollars.

Previous animal trials of CaPre, a highly refined krill-oil based product, showed it dramatically outperformed the current gold standard fish-oil based drug called Lovaza. Lovaza enjoys an ever-growing annual revenue base of over $1 billion.

Lovaza's upstart competitor, Amarin Corp, another fish-oil based drug candidate, reported stellar results over Lovaza in clinical trials and saw its market cap move from the millions to over $1 billion in a market moment.

To read the full news release, please click here.

On another note and for those who may have missed it, highly followed U.S. based financial site, "The Street" recently published a report called "10 Cheap Biotech Stocks That Could Soar"
that included Neptune in its picks. Click here to read the commentary.